in childhood (7) . In another study, the frequency of unbalanced diets with low milk consumption in childhood was higher in adult osteoporotic patients than in control subjects (8) .
A screening serum concentration of vitamin D is suggested for adult patients with Crohn disease who have small-bowel disease or malnutrition or have had upper intestinal resection (2) . The overall vitamin D status is best determined by the serum 25-hydroxyvitamin D concentration. Once adults with Crohn disease have begun corticosteroid therapy, vitamin D 3 supplementation (400 IU by mouth twice daily) should be initiated (2) , and this regimen should be considered for younger patients.
Weight-bearing exercise is important for the maintenance of healthy bone. In a study of 117 older patients with Crohn disease, progressive low-impact exercise was shown to be a potentially effective method of increasing BMD (9); low-intensity exercise of moderate duration does not seem to be associated with an exacerbation of symptoms in patients with Crohn disease (10) . Regular weight-bearing physical activity has been recommended for adults with Crohn disease, and smoking and excessive alcohol intake should also be avoided (2) . These recommendations impose little risk on young patients and could easily be implemented in children and teenagers with Crohn disease.
It is reasonable to consider baseline dual-energy X-ray absorptiometry of the hip and spine in young patients with CD. Measurement of urinary N-telopeptide or of 24-h urinary calcium excretion should also be considered (2) . Urinary N-telopeptide is a highly specific and rapidly responsive marker of osteoclastic activity in bone and can be measured in a spot urine sample. A decrease in the urinary concentration of this peptide is predictive of an increase in bone density. In adult patients who continue to have elevated urinary N-telopeptide or increased urinary calcium excretion, the addition of hydrochlorothiazide (25 mg once or twice a day), combined with dietary sodium restriction, has been suggested (2). Hydrochlorothiazide is beneficial in increasing intestinal calcium absorption and decreasing urinary calcium excretion.
When steroid therapy is initiated, the risk of osteoporosis increases dramatically. Thus, the use of long-term steroids is to be discouraged, and steroids should not be used for maintenance therapy. Once steroid therapy has begun, in addition to the general measures noted above, the following measures are recommended to evaluate ongoing therapy in adults: serial dualenergy X-ray absorptiometry scans and measurement of urinary N-telopeptide and of urinary calcium excretion (2) . At least one study has shown that supplemental fluoride, in combination with vitamin D and calcium, is an effective, well-tolerated, and inexpensive treatment to increase lumbar bone density in patients with Crohn disease and osteoporosis (11) . However, meta-analysis of fluoride therapy has not shown that there is a protective effect on fracture risk in patients with osteoporosis who do not have Crohn disease (4) . Finally, biphosphonates, calcitonin, and hormone replacement therapy are suggested for adults with IBD who are taking steroids (2) . These therapies have not been studied in children and are not appropriate at this point in time for young patients with Crohn disease.
It is obvious that we have much to learn concerning calcium homeostasis, vitamin D status, and osteoporosis in children and young adults with Crohn disease. Sentongo and coworkers are helping us to better understand the pathophysiology of this disease process. Through continued research, perhaps recommendations can be established to minimize the adverse effects of Crohn disease on bone and mineral metabolism in young patients with IBD.
